58 results
8-K
EX-10.1
LIXT
Lixte Biotechnology Holdings Inc
26 Feb 24
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
10:48am
8-K
EX-10.1
LIXT
Lixte Biotechnology Holdings Inc
28 Nov 23
Departure of Directors or Certain Officers
5:21pm
8-K
EX-10.1
mmjn68g16wr3 fox
17 Oct 23
Entry into a Material Definitive Agreement
5:27pm
8-K
EX-10.1
of3a dl7j
27 Sep 23
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
6:15am
8-K
EX-10.1
pzbxfh4g
20 Jul 23
Entry into a Material Definitive Agreement
11:45am
8-K
EX-10.1
dh6xb
15 Apr 22
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
12:00am
8-K
EX-10.1
gol0 wvx5i8
20 Sep 21
Entry into a Material Definitive Agreement
5:21pm
8-K
EX-10.1
x7vckynse2s5
2 Mar 21
VI.Lixte Biotechnology Announces $4.19 Million Registered Direct Offering
4:55pm
8-K
EX-10.1
70d4kmhcd
22 Jan 21
Entry into a Material Definitive Agreement
2:00pm
8-K
EX-10.02
xdb7 hxl7b
18 Aug 20
Entry into a Material Definitive Agreement
4:58pm
8-K
EX-10.01
mmmvg1hq
18 Aug 20
Entry into a Material Definitive Agreement
4:58pm
8-K
EX-10.01
uc4 gkotcr34i0
17 Jul 20
Entry into a Material Definitive Agreement
4:47pm